508543948 05/13/2024

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 Assignment ID: PATI227732

SUBMISSION TYPE:			NEW ASSIGNMENT		
ATURE OF CONVEY	ANCE:		ASSIGNMENT		
CONVEYING PARTY	DATA				
		Ν	lame		Execution Date
2seventy bio, Inc.					04/01/2024
RECEIVING PARTY D	ΟΑΤΑ				
Company Name:	Regene	eron Pl	harmaceuticals, Inc.		
Street Address:	777 OL	D SAV	V MILL RIVER RD		
City:	TARRY	TOWN	N		
State/Country:	NEW Y	ORK			
Postal Code:	10591-0	6707			
PROPERTY NUMBER	29 Total: 1				
Property Type			Number		
		16092	946		
CORRESPONDENCE Fax Number: <i>Correspondence will</i>	DATA	o the e	946 -mail address first; if that is at is unsuccessful, it will be		
CORRESPONDENCE Fax Number: <i>Correspondence will using a fax number, i</i>	DATA be sent to if provideo	o the e	-mail address first; if that is at is unsuccessful, it will be		
CORRESPONDENCE Fax Number: <i>Correspondence will using a fax number, i</i> Phone: Email:	DATA be sent to if provideo	5 the e 1; if tha 61744 mlomb	- <i>mail address first; if that is</i> at is unsuccessful, it will be 96500 pardo@mccarter.com		
CORRESPONDENCE Fax Number: <i>Correspondence will using a fax number, i</i> Phone: Email: Correspondent Name	DATA be sent to if provideo	o the e d; if tha 61744 mlomb Marcie	-mail address first; if that is at is unsuccessful, it will be 96500 pardo@mccarter.com e Clarke		
CORRESPONDENCE Fax Number: <i>Correspondence will using a fax number, i</i> Phone: Email: Correspondent Name Address Line 1:	DATA be sent to if provideo	o the e d; if tha 61744 mlomb Marcie McCar	- <i>mail address first; if that is</i> at <i>is unsuccessful, it will be</i> 96500 pardo@mccarter.com e Clarke rter & English LLP		
CORRESPONDENCE Fax Number: <i>Correspondence will using a fax number, i</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2:	DATA be sent to if provideo	<i>o the e</i> <i>1; if tha</i> 61744 Mlomb Marcie McCar 265 Fr	-mail address first; if that is at is unsuccessful, it will be 96500 pardo@mccarter.com e Clarke ter & English LLP ranklin Street		
CORRESPONDENCE Fax Number: <i>Correspondence will using a fax number, i</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4:	DATA be sent to if provideo	<i>o the e</i> <i>d; if tha</i> 61744 Marcie Marcie Marcie 265 Fr Bostor	-mail address first; if that is at is unsuccessful, it will be 96500 pardo@mccarter.com e Clarke rter & English LLP ranklin Street n, MASSACHUSETTS 02110		
CORRESPONDENCE Fax Number: <i>Correspondence will using a fax number, i</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4:	DATA be sent to if provideo	<i>o the e</i> <i>d; if tha</i> 61744 Marcie Marcie Marcie 265 Fr Bostor	-mail address first; if that is at is unsuccessful, it will be 96500 pardo@mccarter.com e Clarke ter & English LLP ranklin Street		
CORRESPONDENCE Fax Number: <i>Correspondence will using a fax number, i</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4:	DATA be sent to if provideo e: NUMBER:	<i>o the e</i> <i>d; if tha</i> 61744 Marcie Marcie McCar 265 Fr Bostor	-mail address first; if that is at is unsuccessful, it will be 96500 pardo@mccarter.com e Clarke rter & English LLP ranklin Street n, MASSACHUSETTS 02110		
CORRESPONDENCE Fax Number: <i>Correspondence will using a fax number, i</i> Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET I	DATA be sent to if provideo e: NUMBER:	<i>o the e</i> 61744 mlomb Marcie McCar 265 Fr Bostor	-mail address first; if that is at is unsuccessful, it will be 96500 pardo@mccarter.com e Clarke ter & English LLP ranklin Street n, MASSACHUSETTS 02110 137080-00303		
CORRESPONDENCE Fax Number: <i>Correspondence will using a fax number, i</i> Phone: Email: Correspondent Name Address Line 1:	DATA be sent to if provideo e: NUMBER:	o the e 6; if tha 61744 Marcie Marcie 265 Fr Bostor	-mail address first; if that is at is unsuccessful, it will be 96500 pardo@mccarter.com e Clarke ter & English LLP ranklin Street n, MASSACHUSETTS 02110 137080-00303 Michelle Lombardo		
CORRESPONDENCE Fax Number: Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 2: Address Line 4: ATTORNEY DOCKET I NAME OF SUBMITTER BIGNATURE:	DATA be sent to if provided : NUMBER: R:	o the e 6; if tha 61744 Marcie Marcie 265 Fr Bostor	-mail address first; if that is at is unsuccessful, it will be 96500 pardo@mccarter.com e Clarke ter & English LLP ranklin Street n, MASSACHUSETTS 02110 137080-00303 Michelle Lombardo Michelle Lombardo		
CORRESPONDENCE Fax Number: Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 2: Address Line 4: ATTORNEY DOCKET I NAME OF SUBMITTER SIGNATURE: DATE SIGNED: Total Attachments: 12 source=Project Snowbir	DATA be sent to if provided a: NUMBER: R: rd - Patent	Assign	-mail address first; if that is at is unsuccessful, it will be 96500 pardo@mccarter.com e Clarke rter & English LLP ranklin Street n, MASSACHUSETTS 02110 137080-00303 Michelle Lombardo Michelle Lombardo 05/13/2024	<i>sent via US M</i>	f ail.
CORRESPONDENCE Fax Number: Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 2: Address Line 4: Address Line 4: ATTORNEY DOCKET I NAME OF SUBMITTER SIGNATURE: DATE SIGNED: Total Attachments: 12 source=Project Snowbir	DATA be sent to if provided be s: NUMBER: R: rd - Patent and rd - Patent a	Assign	-mail address first; if that is at is unsuccessful, it will be 96500 pardo@mccarter.com e Clarke ter & English LLP ranklin Street n, MASSACHUSETTS 02110 137080-00303 Michelle Lombardo Michelle Lombardo 05/13/2024	<i>sent via US M</i> 0 4.1.24)#page 0 4.1.24)#page	f ail.
CORRESPONDENCE Fax Number: Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 2: Address Line 2: Address Line 2: Address Line 4: ATTORNEY DOCKET I NAME OF SUBMITTER SIGNATURE: DATE SIGNED: Total Attachments: 12 source=Project Snowbir source=Project Snowbir	DATA be sent to if provided be rol - Patent rol - Patent rol - Patent rol - Patent	Assign Assign	-mail address first; if that is at is unsuccessful, it will be 96500 pardo@mccarter.com e Clarke rter & English LLP ranklin Street n, MASSACHUSETTS 02110 137080-00303 Michelle Lombardo Michelle Lombardo 05/13/2024	<i>sent via US M</i> 0 4.1.24)#page 0 4.1.24)#page 0 4.1.24)#page	f ail. 1.tif 2.tif 3.tif

source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page6.tif
source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page7.tif
source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page8.tif
source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page9.tif
source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page10.tif
source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page11.tif
source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page12.tif

EXECUTION VERSION

PATENT ASSIGNMENT AGREEMENT

This Patent Assignment Agreement (this "Assignment") is entered into effective as of April 1, 2024 by and between 2seventy bio, Inc., a Delaware corporation ("Assignor"), and Regeneron Pharmaceuticals, Inc., a New York corporation ("Assignee", together with Assignor, the "Parties"). Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Asset Purchase Agreement (defined below).

WHEREAS, Assignor and Assignee have entered into that certain Asset Purchase Agreement, dated as of January 29, 2024 (as may be amended or restated from time to time, the "Asset Purchase Agreement"), pursuant to which Assignor has agreed to, among other things, sell, assign, transfer, convey, and deliver to Assignee certain Intellectual Property, as more fully described in the Asset Purchase Agreement, on the terms and subject to the conditions set forth in the Asset Purchase Agreement; and

WHEREAS, such Intellectual Property includes, without limitation, the Patents set forth on <u>Annex</u> <u>A</u> hereto (collectively, the "Transferred Patents").

NOW, THEREFORE, pursuant to the Asset Purchase Agreement, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. <u>Assignment</u>. Assignor hereby sells, assigns, transfers and delivers to Assignee, and Assignee hereby purchases and acquires from Assignor, all rights, titles, and interests of Assignor in, to and under the Transferred Patents in the United States and in all foreign countries (including, without limitation, all rights therein provided by international conventions and treaties), including, without limitation, any priority applications, applications for patent, patents, reissues, divisions, continuations, continuations-in-part, extensions, re-examinations and foreign equivalents thereof, all rights to claim priority thereto or therefrom, and all rights therein provided by international treaties and conventions, together with all associated income, royalties, damages or payments accrued, due or payable as of the Effective Date or thereafter and including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Transferred Patents, with the right to sue for, and collect the same, in each case, for Assignee's own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made. Assignee acknowledges that Assignor makes no representations or warranties with respect to the Transferred Patents except as specifically set forth in the Asset Purchase Agreement.

2. <u>Recordation</u>. Assignor hereby authorizes and requests that the United States Patent and Trademark Office Commissioner for Patents (the "USPTO") and any other applicable Governmental Authority or registrar (including any applicable foreign or international office or registrar) record this Assignment and record Assignee as the assignee and owner of the Transferred Patents. Assignor further authorizes and requests the USPTO and any other applicable Governmental Authority or registrar (including any applicable foreign or international office or registrar) to transfer all registrations and registration applications included in the Transferred Patents to Assignee as purchaser of Assignor's rights, titles and interests therein, in accordance with this Assignment, and to issue to Assignee all registrations that may issue with respect to any applications for registration of patent rights included in such Transferred Patents.

3. Further Assurances.

3.1 Upon Assignee's reasonable request and without further compensation, Assignor shall execute, acknowledge and deliver all such other instruments and documents and shall take all such other actions reasonably necessary or required by Law to consummate and make fully effective the transaction contemplated by this Assignment.

3.2 If Assignee is unable for any reason to secure any of Assignor's signatures to any document required to file, prosecute, register or memorialize the assignment of any rights under any Transferred Patents as provided under this Assignment, then Assignor hereby irrevocably designates and appoints Assignee and Assignee's duly authorized officers and agents as Assignor's agents and attorneys-in-fact to act for and on each of Assignor's behalf and instead of Assignor to take all lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, issuance, and enforcement of rights under such Transferred Patents, all with the same legal force and effect as if executed by Assignor. The foregoing is deemed a power coupled with an interest and is irrevocable.

4. <u>No Third-Party Beneficiaries</u>. Nothing in this Assignment, express or implied, is intended or shall be construed to confer upon, or to give to, any Person other than Assignee and its successors and assigns any remedy or claim under or by reason of this Assignment or any terms, covenants or conditions hereof, and all the terms, covenants and conditions, promises and agreements in this Assignment contained shall be for the sole and exclusive benefit of Assignee and its respective successors and assigns.

5. <u>Interpretation</u>. This Assignment is intended to implement the provisions of the Asset Purchase Agreement, is expressly subject to the terms and conditions thereof, and shall not be construed to enhance, extend or limit the representations and warranties, rights, obligations or remedies of either Party. In case of any conflict or inconsistency between the terms and conditions of this Assignment and the terms and conditions of the Asset Purchase Agreement, the terms and conditions of the Asset Purchase Agreement shall govern.

6. <u>Amendment</u>. Except as otherwise provided herein, no amendment, modification or supplement of any provision of this Assignment shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party.

7. <u>Waiver</u>. No provision of this Assignment shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party.

8. <u>Governing Law</u>. This Assignment shall be governed and construed in accordance with the Laws of the State of Delaware, without giving effect to any choice of law provisions thereof that would result in the application of the Law of any jurisdiction other than Delaware. The Parties hereby irrevocably submit to the exclusive jurisdiction of the Court of Chancery of the State of Delaware sitting in the New Castle County (or, only if the Court of Chancery of the State of Delaware declines to accept or does not have jurisdiction over a particular matter, any federal or other state court sitting in New Castle County within the State of Delaware), and the appellate courts having jurisdiction of appeals in such courts, in each case, over any dispute arising under this Assignment and each Party hereby irrevocably agrees that all claims in respect of this Assignment shall be heard and determined in such courts. The Parties hereby irrevocably waive, to the fullest extent permitted by applicable Law, any objection which they may now or hereafter have to the laying of venue of any such claim brought in such court or any defense of inconvenient forum for the

maintenance of such claim. Each of the Parties agrees that a judgment in any such dispute may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.

9. <u>Counterparts</u>. This Agreement may be executed in one or more counterparts, and signature pages may be delivered by portable document format (PDF), DocuSign or any other electronic signature complying with the U.S. federal ESIGN Act of 2000, the Delaware Uniform Electronic Transactions Act, and any other applicable Law, each of which shall be deemed an original, but all of which will be considered one and the same agreement and will become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party, it being understood that all Parties need not sign the same counterpart.

[Signature page follows]

IN WITNESS WHEREOF, Assignor intending to be legally bound has caused this Assignment to be executed by its duly authorized representatives as of the Effective Date.

ASSIGNOR:

2SEVENTY BIQ, INC Bv:

Name: Nick Leschly

Title: President and Chief Executive Officer

Witness:

nder 03-19-04

Witness: 3-19-24

Name and date

COMMONWEALTH OF M) A SEACHUSE HS)

) SS.

)

COUNTY OF Middleset

On this 17 day of March, 2024, there appeared before me______ Nick Leschly personally known to me, who acknowledged that he/she signed the foregoing Assignment as his/her voluntary act and deed on behalf and with full authority of 2seventy bio, Inc.

KELLEY J. DOLLIVER **Notary Public** IONWEALTH OF MASSACHUSETTS My Commission Expires On October 07, 2027

Nelly A Dolly

[Signature Page to Patent Assignment Agreement]

IN WITNESS WHEREOF, Assignee intending to be legally bound has caused this Assignment to be executed by its duly authorized representatives as of the Effective Date.

ASSIGNEE:

REGENERON PHARMACEUTICALS, INC.

By:

Name: Nouhad Husseini

Title: Senior Vice President, Head of Business **Development and Corporate Strategy**

Paige Cooperman Paige Cooperman Pauje / 3/11/2024

Witness: Victoria A. Thiele - Gambino Vitnis a. Thiele Hambin 3/11/2024

Name and date

STATE OF New York)

) SS.

COUNTY OF Wostches ter

On this <u>11</u>th day of March, 2024, there appeared before me Nouhad Husseini_, personally known to me, who acknowledged that he/she signed the foregoing Assignment as his/her voluntary act and deed on behalf and with full authority of Regeneron Pharmaceuticals, Inc.

NANCY FERRARA NOTARY PUBLIC, STATE OF NEW YORK NO. 03-4823560 **QUALIFIED IN WESTCHESTER COUNTY** COMMISSION EXPIRES JUNE 30, 2027

Notary Public

[Signature Page to Patent Assignment Agreement]

Exhibit A

Transferred Patents

[Exhibit A to Patent Assignment Agreement]

2seventy Ref. BLUE-092AU BLUE-092D1 BLUE-092CA BLUE-092CN	BLUE-080.US BLUE-080.ZA	BLUE-080.SE BLUE-080.SG	BLUE-080.PC	BLUE-080.NZ	BLUE-080.MX	BLUE-080.JP2 BLUE-080.KR	BLUE-080.JP	BLUE-080.IN BITE-080 IT	BLUE-080.1L2	BLUE-080.IE	BLUE-080.HK	BLUE-080.FR	BLUE-080.ES	BLUE-080.EP BLUE-080.EP2	BLUE-080.EA	BLUE-080.DK	BLUE-080.CN2	BLUE-080.CN	BLUE-080.CA	BLUE-080.C1	BLUE-080.BR	BLUE-080.AU2	BLUE-080.AU	2seventy Ref.	BLUE-068USPC	BLUE-068PC	BLUE-068P1	BLUE-068JP	BLUE-068EP	BLUE-068CN	BLUE-068AU	2seventy Ref.	BLUE-036USPC	BLUE-036PC	BLUE-036P1 BLUE-036P2	BLUE-036NL	BLUE-036JP3	BLUE-036JP BLUE-036JP2	BLUE-036IT	BLUE-036HK2 BLUE-036IE	BLUE-036HK	BLUE-036FR BLUE-036GB	BLUE-036ES	BLUE-036EP2	BLUE-036DK	BLUE-036DE	BLUE-036CIP	BLUE-036CH	BLUE-036CA	BLUE-036C3 BLUE-036C4	BLUE-036C2	BLUE-036C1	BLUE-036AU2	BLUE-036AU	Terrente Daf
RIGHTS Owned by 2seventy Owned by 2seventy Owned by 2seventy Owned by 2seventy	Owned by 2seventy Owned by 2seventy	Owned by 2seventy Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by Zseventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy Owned by 2seventy	Owned by 2seventy	Owned by 2seventy Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	RIGHTS Dwmad hv Jsavanty	Owned by 2seventy	Owned by Zseventy	Owned by 2seventy	RIGHTS	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy Owned by 2seventy	Owned by 2seventy	Owned by 2seventy Owned by 2seventy	Owned by 2seventy	Owned by 2seventy Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	Owned by 2seventy	PIQUTE				
CO Serial No. AU 2018385699 US 18/595641 CA 3064551 CN 201880086118.7	US 16/348450 ZA 2019/03076	SE 17872043.90 SG 11201904353S	US 62/467496 PCT PCT/US17/62358	NZ 753521.00	MX MX/a/2019/005724	JP 2023-64901 KR 10-2019-7017172	JP 2019-526305	IN 201917022415.00	IL 309526.00	IE 17872043.90	HK 19130700.80	FR 17872043.90	ES 17872043.90	EP 17872043.90 EP 23216595.10	EA 201991186.00	DE 17872043.90 DK 17872043.90		CN 201780077533.10			BR BR1120190099042			CO Serial No. AT 17877043.90	US 16/092946	WO PCT/US2017/027606	US 62/322634			CN 201780034987.0	AU 2017250773		US 14/908734	WO PCT/US2014/047852	US 61/859697 US 61/934092			JP 2016-531761 JP 2019-112035		HK 42022055546.0 IE 14832043.5		FR 14832043.5 GB 14832043.5		EP 14832043.5 EP 21162954.8		DE 14832043.5		CH 14832043.5	CA 2956667	US 16/573254 US 17/675246	US 16/540673	BE 14832043.5 US 16/219640		AU 2014296626	CO Serial No
Publication No. 2018385699 3084551 111565737	US 2019/0350974 A1	3541833	WO 2018/094244 A1		TBA 3541833	2023-89135 10-2019-0077562	2019-535275	30/2019		3541833	40007184 A	3541833	3541833	3541833	201991186	3541833 3541833		5341633 CN 110072885 A	3043888	US-2023-0364141	001900	00000		Publication No.	US-2022-0195039-A1			2019-518425	3443002	3020995 109311963	2017250773	Publication No.		WO 2015/017214		3027204		2016-531567 2019-146598	3027204	40066967 A 3027204	1224194	3027204 3027204	3027204	3027204 3925618	3027204	3027204	US 2015-0266973 A1	3027204	2956667	US-2020-0071401-A1	US 2020-0071399 A1	3027204 US 2019-0112372 A1	2019203955	2014296626	Publication No.
DARC NTERLEUKIN RECEPTORS DARC INTERLEUKIN RECEPTORS DARC INTERLEUKIN RECEPTORS DARC INTERLEUKIN RECEPTORS	TGF BETA SIGNAL CONVERTOR TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGE BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGFBETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGF BETA SIGNAL CONVERTOR	TGE RETA SIGNAL CONVERTOR	SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS		MULTIPARTITE SIGNALING PROTEINS AND USES THEREOP	MULTIPARTITE SIGNALING PROTEINS AND USES THER	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTIE SIGNALING PROTEINS AND USES THEREOF MULTIPARTIE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF												
																																	EOF	ĝ g	ç ç	Ŷ	Ę	99	ĝ	99	<u>o</u> r	<u> </u>	REOF	REOF	REOF	REOF	Ê Ç	Ē,	ő (99	9	99	ģ ģ	윾	
Application Title																								Application Title								Application Title	EOF	0	EOF	0F	EOF	OF F	OF	<u>0</u>	EOF	EOF	REOF	REOF	REOF	REOF	ROF	EOF	EOF		0F	99	0	OF	Anadioastine Tiste
	11/	11/ 11/	1/1 05/1	11/	11/	11/	11/	11/	11/	11/	11/	11/	11/	11/	11/	11/	11/	11/	11/	11/	11/	11/			04/	04/	04/	04/	04/	04/	04/																								
Priority Date 12/14/2017 12/14/2017 12/14/2017 12/14/2017			03/06/2017 03/ 11/17/2016 11/						11/17/2016 12/		11/17/2016 11/					11/17/2016 11/ 11/17/2016 11/					11/17/2016 11/ 11/17/2016 11/	11/17/2016 11/	11/17/2016 11/	Priority Date 11/17/2014			04/14/2016 04/					Priority Date	07/29/2013	07/29/2013	07/29/2013	07/29/2013	07/29/2013	07/29/2013	07/29/2013	07/29/2013 07/29/2013	07/29/2013	07/29/2013	07/29/2013	07/29/2013	07/29/2013	07/29/2013	07/29/2013	. 07/29/2013	07/29/2013	07/29/2013	07/29/2013	- 07/29/2013 - 07/29/2013	- 07/29/2013	07/29/2013	Priority Date
Priority Date Filing Date 12/14/2017 05/18/2020 12/14/2017 05/05/2020 12/14/2017 05/05/2020 12/14/2017 07/10/2020	11/17/2017 05/16/2019		03/06/2017 03/06/2017 03/06/2017 03/06/2017 03/06/2017				11/17/2017	11/17/2016 11/17/2017 11/17/2016 11/17/2017										11/17/2016 11/17/2017				11/17/2017	11/17/2017	Priority Date Filing Date		04/14/2016 04/14/2017		10/12/2018				Priority Date Filing Date	07/29/2013 01/29/2016		07/29/2013	07/29/2013 02/23/2016	07/29/2013 05/27/2020	07/29/2013 01/27/2016 07/29/2013 07/23/2014	07/29/2013 02/23/2016	07/29/2013 06/22/2022 07/29/2013 02/23/2016	07/29/2013 10/31/2016	07/29/2013 02/23/2016	07/29/2013 02/23/2016	07/29/2013 02/23/2016 07/29/2013 03/16/2021	07/29/2013 02/23/2016	07/29/2013 02/23/2016	07/29/2013 01/28/2015	07/29/2013 02/23/2016	07/29/2013	07/29/2013 09/17/2019	07/29/2013 08/14/2019	- 07/29/2013 12/13/2018	27/29/2013 06/06/2019		Brindhy Date Filing Date
Priority Date 12/14/2017 12/14/2017 12/14/2017 12/14/2017													11/17/2017	11/17/2017 12/14/2023	11/17/2017	11/17/2017 11/17/2017	11/30/2023	11/17/2017	11/17/2017			11/17/2017	11/17/2016 11/17/2017 03/31/2022	Priority Date 11/17/2014								Priority Date	07/29/2013	07/29/2013	07/29/2013	07/29/2013 02/23/2016	07/29/2013	07/29/2013	07/29/2013 02/23/2016	07/29/2013 06/22/2022 07/29/2013 02/23/2016	07/29/2013 10/31/2016	07/29/2013	07/29/2013	07/29/2013	07/29/2013 02/23/2016	07/29/2013 02/23/2016	07/29/2013	07/29/2013 02/23/2016	07/29/2013	07/29/2013	07/29/2013 08/14/2019	- 07/29/2013 12/13/2018 -	27/29/2013 06/06/2019	07/29/2013	Brindhy Date Filing Date
Priority Date Filing Date 12/14/2017 05/18/2020 12/14/2017 05/05/2020 12/14/2017 05/05/2020 12/14/2017 07/10/2020	11/17/2017 05/16/2019	11/17/2017		11/17/2017	11/17/2017	11/17/2017	11/17/2017 04/14/2023		12/19/2023		11/17/2017		11/17/2017		11/17/2017	11/17/2017 11/17/2017	11/30/2023	11/17/2017	11/17/2017	04/07/2023	11/17/2017	11/17/2017	11/17/2017 03/31/2022	Priority Date Filing Date		04/14/2017		10/12/2018 08/16/2022	11/13/2018	12/05/2018	10/17/2018	Priority Date Filing Date	07/29/2013 01/29/2016	07/29/2013 07/23/2014	07/29/2013	07/29/2013 02/23/2016 01/05/2022	07/29/2013 05/27/2020 09/02/2020	07/29/2013 01/27/2016 07/29/2013 07/23/2014	07/29/2013 02/23/2016 01/05/2022	07/29/2013 06/22/2022 07/29/2013 02/23/2016 01/05/2022	07/29/2013 10/31/2016	07/29/2013 02/23/2016 01/05/2022	07/29/2013 02/23/2016	07/29/2013 02/23/2016 01/05/2022 07/29/2013 03/16/2021		07/29/2013 02/23/2016 01/05/2022	07/29/2013 01/28/2015	07/29/2013 02/23/2016 01/05/2022	07/29/2013 01/27/2017	07/29/2013 09/17/2019 12/20/2022	07/29/2013 08/14/2019	: 22024co/to at/2/21/2013 12/13/2018 10/29/2019 -			Priority Date Filing Date Jesus Date

2seventy Ref. BLUE-115.BU BLUE-115.CR BLUE-115.CR BLUE-115.CN BLUE-115.CN BLUE-115.EA BLUE-115.EA	2seventy Ref. BLUE-114P1 BLUE-114P2 BLUE-114P2 BLUE-114PC BLUE-114USPC	2200000119 Ref. BLUE-1133AK BLUE-1133A BLUE-113CA BLUE-113CA BLUE-113CA BLUE-1131R BLUE-1131R BLUE-1131R BLUE-11312 BLUE-11312 BLUE-11312	2seventy Ref. BLUE-112-IH BLUE-112CA BLUE-112CA BLUE-112CA BLUE-112CP BLUE-112P BLUE-112P BLUE-112P2 BLUE-112P2 BLUE-112P2 BLUE-112P2	2seventy Ref. BLUE-111P1 BLUE-111PC BLUE-111USPC	Zeventy Ref. BLUE-103.HK BLUE-103CN BLUE-103CP BLUE-103P BLUE-103P1 BLUE-103P1 BLUE-103PC	2:eventy Ref. BULE-DDIAR BULE-DDIAR BULE-DDIAR BULE-DDICN BULE-DDICN BULE-DDIAR BULE-DDIAR BULE-DDIAR BULE-DDIAR BULE-DDIAR BULE-DDIAR BULE-DDIAR BULE-DDIAR BULE-DDIAR BULE-DDIAR BULE-DDIAR BULE-DDIAR	2:eventy Ref. BLUE-098EP BLUE-098P1 BLUE-098PC BLUE-098USPC	BLUE-092EP BLUE-0921K BLUE-0921R BLUE-0927R BLUE-0927R BLUE-0927C BLUE-0927C
RIGHTS Gr-Owned Middigene/Zewenty Gr-Owned Middigene/Zewenty Gr-Owned Middigene/Zewenty Gr-Owned Middigene/Zewenty Gr-Owned Middigene/Zewenty Gr-Owned Middigene/Zewenty	RIGHTS Owned by Zseventy Owned by Zseventy Owned by Zseventy Owned by Zseventy	RIGHTS Owned by Zseventy Owned by Zseventy	RIGHTS Owned by Zseventy Owned by Zseventy	RIGHTS Owned by 2seventy Owned by 2seventy Owned by 2seventy	RIGHTS Owned by Zseventy Owned by Zseventy	RIGHTS Owned by Zseventy Owned by Zseventy	RIGHTS Owned by Zseventy Owned by Zseventy Owned by Zseventy Owned by Zseventy	Owned by 2seventy Owned by 2seventy
CO Serial No. AU 2020/45588.00 BR BR112021019066-0 CL 313-4076.00 CL 20210/2491.00 CN 20208/0334/52.40 CO NC/021/00128/7 EA 202192327.00	CO Serial No. US 62/779953 US 62/835662 WO PCT/US2019/066241 US 17/312116	CO Serial No. HK 62023051933.0 AL 201939653.0 CA 3123084 CA 31	CO Scrial No. HK 620230519206 AU 2019397120 CA 3121942 CH 2019806094083 EP 1989607931 JP 2021-533529 US 62/779880 US 62/779880 US 62/77980 US 62/77980	CO Serial No. US 62/779882 WO PCT/US2019/066216 US 17/311767	CO Serial No. HK 62022054426.1 AU 2020211990 CN 202080016565.2 EP 2021-543160 US 62/795513 WO PCT/V152020/014668 US 17/425309	Serial No. Serial No. N2 771249 AU 2019287720 BR BR110020025433-8 CA 3110836 CA 3110836 CA 3110836 CA 20192005433-8 CA 3110836 CA 201920054372.5 EP 24150405.90 HK 62021040549.7 IL 279310 ID 20205-561179 IP 20205-561179 IP 20205-561179 ID 202145-56179 ID 202145-56179 ID 20215-56179 </td <td>CO Serial No. EP 19784626.4 US 62/657388 WO PCT/US2019/027317 US 17/046466</td> <td>EP 1888801.0 HK 62021028403.5 IL 275079 JP 2020-532804 KR 10-2020-7020228 US 62/598923 WO PCT/US2018/065786 US 16/771402</td>	CO Serial No. EP 19784626.4 US 62/657388 WO PCT/US2019/027317 US 17/046466	EP 1888801.0 HK 62021028403.5 IL 275079 JP 2020-532804 KR 10-2020-7020228 US 62/598923 WO PCT/US2018/065786 US 16/771402
Publication No. BR112021019066-0 A2 3134076 CN 114126716 A 2021/0012587 202192327	Publication No. WO 2020/123947 US-2022-0025014-A1	Publication No. 40063502 201939653 3123084 113366479 3895052 283897 283897 283897 283897 283897 2825052 2825052 2825052 2002-513460 10-2021-0104772 10-2021-0104772 400 2020/123938 400 2020/123938	Publication No. 4065301 A 2019397152 3121992 113412276 3894436 2022-512475 2022-512475 WO 2020/123936	Publication No. WO 2020/123933	Publication No. 4005383A 2020211990 114206103 3914067 2022-523044 WO 2020/154445 US-2022-0106610-A1	Publication No. 7712,49 2019287720 8110836 3110836 3110836 3110836 3110836 3110836 3110326 3110326 3112368021 320152700 279312 270352 270352 270352 270352 270352 270352 270352 270352 270352 270352 270352 270352 270352 270352 270352 270352 270325 2715255 2715555 2715555 2715555 2715555 27155555 27155555 2715555555555	Publication No. 3781188 WO 2019/200316 US-2021-0252084-A1	3723787 40038635 275079 2021-506271 10-2020-0110326 WO 2019/118895 US-2020-0392204-A1
MAGE AI T CELL RECEPTORS MAGE AI T CELL RECEPTORS	APP OMERZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES DIMERZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES DIMERZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES DIMERZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	ABD OWERCING VEEN. BEGUTATED INWUNOBECELOB CONNERSE OWERCING VEEN. BEGUTATED INWUNOBECELOB. BEGUTATED VEEN. BEGUTA	APP OMERZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES OMERZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	APP OMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	AF METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	CD79A, CHIMERIC ANTIGEN RECEPTORS CD79A, CHIMERIC ANTIGEN RECEPTORS	ADOPTIVE CELLULAR THERAPY ADOPTIVE CELLULAR THERAPY ADOPTIVE CELLULAR THERAPY ADOPTIVE CELLULAR THERAPY	DARIC INTERLEUKIN RECEPTORS DARIC INTERLEUKIN RECEPTORS DARIC INTERLEUKIN RECEPTORS DARIC INTERLEUKIN RECEPTORS DARIC INTERLEUKIN RECEPTORS DARIC INTERLEUKIN RECEPTORS
Application Ttle	Application Title TTOR COMPLEXES TTOR COMPLEXES TTOR COMPLEXES	PTOR COMPLEXES PTOR COMPLEXES PTOR COMPLEXES PTOR COMPLEXES PTOR COMPLEXES PTOR COMPLEXES PTOR COMPLEXES PTOR COMPLEXES PTOR COMPLEXES PTOR COMPLEXES	EPTOR COMPLEXES EPTOR COMPLEXES EPTOR COMPLEXES EPTOR COMPLEXES EPTOR COMPLEXES EPTOR COMPLEXES EPTOR COMPLEXES EPTOR COMPLEXES EPTOR COMPLEXES	Application Title EPTOR COMPLEXES EPTOR COMPLEXES EPTOR COMPLEXES	Application Title (6 VIAL VECTORS (6 VIAL VECTORS (6 VIAL VECTORS (6 VIAL VECTORS (6 VIAL VECTORS (6 VIAL VECTORS) (6 VIAL VECTORS	Application Title	Application Title	
Application Title Priority Date Filing Date ssue Date 03/27/2010 03/27/2010 03/27/2020 03/27/2020 03/27/2010 03/27/2010 03/27/2020 03/27/2020 03/27/2010 03/27/2010 03/27/2020 03/27/2020 03/27/2010 03/27/2010 03/27/2020 03/27/2020 03/27/2010 03/27/2010 03/27/2020 03/27/2020	Silication Title Priority Date Filing Date Issue Date 21/4/2018 21/4/2018 12/1/4/2018 04/18/2019 12/14/2018 12/13/2019 12/14/2018 06/09/2021	Pication Title Priority Date Filing Date Issue Date 12/14/2018 66/09/2021 12/14/2018 66/09/2021 12/14/2018 66/09/2021 12/14/2018 66/03/2021 12/14/2018 66/03/2021 12/14/2018 66/03/2021 12/14/2018 66/01/2021 12/14/2018 66/01/2021 12/14/2018 66/01/2021 12/14/2018 66/01/2021 12/14/2018 66/01/2021 12/14/2018 66/01/2021 12/14/2018 62/01/2021 12/14/2018 62/09/2021 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018	Silardion Title Priority Date Filing Date Suse Date 12/14/2018 06/09/2021 12/14/2018 06/09/2021 12/14/2018 07/08/2021 12/14/2018 07/08/2021 12/14/2018 07/08/2021 12/14/2018 02/11/2021 12/14/2018 02/11/2021 12/14/2018 02/11/2021 12/14/2018 02/11/2021 12/14/2018 02/11/2021	Silcation Title Priority Date Filing Date Issue Date 12/14/2018 12/14/2018 12/14/2018 12/13/2019 12/14/2018 05/08/2021	Plication Title Priority Date Filing Date Issue Date 01/22/2019 01/22/2019 01/22/2019 01/22/2019 01/23/2019 07/22/2019 01/23/2019 01/23/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2019 01/25/2012	. Of-functive Date Filing Date Susce Date 06/14/2018 12/17/2020 06/14/2018 12/17/2020 06/14/2018 12/17/2020 06/14/2018 12/07/2021 06/14/2018 12/07/2021 06/14/2018 12/07/2021 06/14/2018 12/07/2021 06/14/2018 12/07/2021 06/14/2018 12/07/2021 06/14/2018 06/14/2018 06/14/2018 06/14/2018 06/14/2018 06/14/2018 06/14/2018 06/14/2018	Priority Date Filing Date Issue Date 04/13/2018 10/21/2020 04/13/2018 04/13/2018 04/13/2018 04/12/2019 04/13/2018 10/09/2020	12/14/2017 06/11/2020 12/14/2017 03/29/2021 12/14/2017 05/29/2021 12/14/2017 06/12/2020 12/14/2017 07/13/2020 12/14/2017 12/14/2018 12/14/2017 12/14/2018 12/14/2017 06/10/2020
Priority Date Filing Date 93/27/2019 03/27/2020 03/27/2019 03/27/2020 03/27/2019 03/27/2020 03/27/2019 03/27/2020 03/27/2019 03/27/2020 03/27/2019 03/27/2020	silication Title Priority Date Filing Date 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/13/2019 12/14/2018 06/09/2021	plication Title Priority Date Filing Date 12/14/2018 06/9/2022 12/14/2018 06/9/2022 12/14/2018 06/9/2022 12/14/2018 06/9/2021 12/14/2018 06/12/2021 12/14/2018 06/11/2021 12/14/2018 06/11/2021 12/14/2018 06/11/2021 12/14/2018 06/19/2021 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018 06/19/2021	silariton Title Priority Date Filing Date 12/14/2018 09/2022 12/14/2018 09/2022 12/14/2018 09/2021 12/14/2018 07/2021 12/14/2018 07/2021 12/14/2018 07/2021 12/14/2018 07/08/2021 12/14/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018 06/08/2021	Silication Title Priority Date Filing Date 12/4/2018 12/14/2018 12/14/2018 12/14/2018 12/14/2018 05/08/2021	plication Title Priority Date Filing Date 01/23/2019 66/1/2022 01/23/2019 07/22/2020 01/24/2019 07/22/2020 01/25/2019 07/25/2021 01/25/2019 07/25/2021 01/25/2019 01/22/2020 01/25/2019 07/22/2021	 Pickniky Date: Elling Late: 66/4/2018: 12/17/2020 66/14/2018: 12/17/2020 66/14/2018: 12/17/2020 66/14/2018: 12/17/2020 66/14/2018: 12/12/2020 	Priority Date Filing Date 04/13/2018 10/21/2020 04/13/2018 04/12/2019 04/13/2018 04/12/2019 04/13/2018 10/09/2020	

2.exemty Ref. BLUE-123AU BLUE-123AA BLUE-123AA BLUE-123AA BLUE-123AA BLUE-123AA BLUE-123AA BLUE-123AA BLUE-123AA BLUE-123AA BLUE-123AA	BLUE-122.AU BLUE-122.CA	2seventy Ref.	BLUE-120102 BLUE-12011 BLUE-12010 BLUE-1200N BLUE-120NX BLUE-120NX BLUE-120NS BLUE-120NS BLUE-120NS BLUE-120NSPC	2seventy Ref. BLUE-120AU BLUE-120CA BLUE-120CA BLUE-120CN BLUE-120EP BLUE-120EP BLUE-120HK BLUE-120HK	BUDE-1190 BUDE-1	2:eventy Ref. BLUE-119AU BLUE-119AR BLUE-119CN BLUE-119CA BLUE-119EA BLUE-119EF BLUE-119FF	BLUE-115.EP2 BLUE-115.HV2 BLUE-115.HV2 BLUE-115.HV BLUE-115.FK BLUE-115.FK BLUE-115.FK BLUE-115.FK BLUE-115.FK
BIGHTS Owned by Zeventry Owned by Zeventry	Gr-Owned Medigens/Zaventry Gr-Owned Medigens/Zaventry	RIGHTS	G-Owned Inbitry/Zseverty G-Owned Inbitry/Zseverty G-Owned Inbitry/Zseverty G-Owned Inbitry/Zseverty G-Owned Inbitry/Zseverty G-Owned Inbitry/Zseverty G-Owned Inbitry/Zseverty G-Owned Inbitry/Zseverty G-Owned Inbitry/Zseverty	RIGHTS Go-Owned Inhibry/Seventy Go-Owned Inhibry/Seventy Go-Owned Inhibry/Seventy Go-Owned Inhibry/Seventy Go-Owned Inhibry/Seventy Go-Owned Inhibry/Seventy Go-Owned Inhibry/Seventy	Co-Owned Inhibry/Jseverty Co-Owned Inhibry/Jseverty Co-Owned Inhibry/Jseverty Co-Owned Inhibry/Jseverty Co-Owned Inhibry/Jseverty Co-Owned Inhibry/Jseverty Co-Owned Inhibry/Jseverty Co-Owned Inhibry/Jseverty Co-Owned Inhibry/Jseverty Co-Owned Inhibry/Jseverty	RIGHTS Go-Owned Inhibry/Iseventy Go-Owned Inhibry/Iseventy Go-Owned Inhibry/Iseventy Go-Owned Inhibry/Iseventy Go-Owned Inhibry/Iseventy Go-Owned Inhibry/Iseventy	Co-Owned Medigene/Zeventy Co-Owned Medigene/Zeventy Co-Owned Medigene/Zeventy Co-Owned Medigene/Zeventy Co-Owned Medigene/Zeventy Co-Owned Medigene/Zeventy Co-Owned Medigene/Zeventy Co-Owned Medigene/Zeventy Co-Owned Medigene/Zeventy
AV 2022/22 AV 2022/22 BF 641/02/10/5/25/9-2 CA 314328 CV 202060052834/0 F 2022/00/05 F 2022/00/5/6 B 2022/2027/0 B P02022/2027/0 L 2889/4 N 2022/700/553	AJ 2020/6/64.100 BR BR112/01/22/343-7 CA 31390/11/00 CC 2021/02/35/00 CC 2021/02/35/00 CC 2021/02/36/00 EF 2080/73/00/643 EF 2080/73/00/643 EF 2080/73/00/643 EF 2082/200/643 EF 20221/95/24/11/00 FF 20221/95/24/11/95/	co Serial No.		CO Serial No. AU 202026/639 BR BR1202102365-7 CA 3148027 CA 3148027 CN 202080049880.5 EA 202193071 EP 20801987.7 HK 6202205963.7 ID p00202105926		CO Serial No. AU 2020268379 BR BR112021022356-8 CA 3139096 CA 202080048661.5 EA 202193072 EP 20802310.1 EP 20802310.1	EP 2071942.30 HK 62023056770.00 ID 900202107870 IL 28559.00 IL 28559.00 IN 2021.50902 KK 10-2021.708302 KK 10-2021.708302 KK 10-2021.708302 SC 120221101710 US 17/441861
Publication No. 2020;29:922 3143;48 C:V11:420:6936 2022;90071 3983;445 4007;24:64 2023;/04181 2023;170:00553	202026/641 213/5069 CV114375301A NC2021/0016480 202139070 2023/02860 202137052411 A 2022-512557 10-2022-0039833 10-2022-0039833 NO 2020/227483 A1 2023-00445880	Publication No.	287769 2022-53256 10-2022-0931549 Wo 2020/227475 112021119270 US-2022-0323496-A1	Publication No. 2020267639 BR112021022365-7 3148027 114502586A 3966249 40071126 2022/01934		Publication No. 2020268379 BR112021022356-8 3139096 114206928 202193072 39663251 39663251 40071127 A	3936621 HK40067706 2022-527635 10-2021-0150440 A WO 2023/015967 A1 US 2023/0159612 A1
COMPOSITIONS AND METHODS FOR TREATING CANCER COMPOSITIONS AND METHODS FOR TREATING CANCER	ENCINEERED TELLS ENCINEERED TELLS		CL-1 TARGETED IMMUNOTHERAPIES CL-1 TARGETED IMMUNOTHERAPIES	CL-1 TARGETED IMMUNOTHERAPIES CLL-1 TARGETED IMMUNOTHERAPIES CLL-1 TARGETED IMMUNOTHERAPIES CLL-1 TARGETED IMMUNOTHERAPIES CLL-1 TARGETED IMMUNOTHERAPIES CLL-1 TARGETED IMMUNOTHERAPIES CLL-1 TARGETED IMMUNOTHERAPIES	C033 TARGETED MM/UNOTHERAPIS C033 TARGETED MM/UNOTHERAPIS	C031 TARGETED IMMUNOTHERAPIIS C031 TARGETED IMMUNOTHERAPIIS C031 TARGETED IMMUNOTHERAPIIS C031 TARGETED IMMUNOTHERAPIIS C031 TARGETED IMMUNOTHERAPIIS C031 TARGETED IMMUNOTHERAPIIS C031 TARGETED IMMUNOTHERAPIIS	MAGE AT T CELL RECEPTORS MAGE AT T CELL RECEPTORS
NCER NCER NCER							
Application Title NUCER NUCER NUCER NUCER NUCER NUCER NUCER NUCER NUCER		Application Title		Application Title		Application Title	
Application Title							
Application Title Periodicy Date: 06(14)/2019 Old Title Date: 06(14)/2019 Old Titl	36/08/2012 36/08/2012 36/08/2012 36/08/2012 36/08/2012 36/08/2012 36/08/2012 36/08/2012 36/08/2012 36/08/2012 36/08/2013 36/07/2020 <t< th=""><th>Priority Date Filing Date</th><th></th><th>Priority Date Filing Date 55(98/2019 12/05/2021 05(98/2019 12/05/2021 05(98/2019 11/02/2021 05(98/2019 12/05/2021 05(98/2019 12/05/2021 05(98/2019 05/07/2022 05(98/2019 05/07/2022</th><th></th><th>Priority Date Filing Date 05/08/2019 12/06/2021 05/08/2019 05/07/2021 05/08/2019 05/07/2021 05/08/2019 12/08/2021 05/08/2019 12/08/2021 05/08/2019 05/07/2021</th><th>04/27/2019 04/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020</th></t<>	Priority Date Filing Date		Priority Date Filing Date 55(98/2019 12/05/2021 05(98/2019 12/05/2021 05(98/2019 11/02/2021 05(98/2019 12/05/2021 05(98/2019 12/05/2021 05(98/2019 05/07/2022 05(98/2019 05/07/2022		Priority Date Filing Date 05/08/2019 12/06/2021 05/08/2019 05/07/2021 05/08/2019 05/07/2021 05/08/2019 12/08/2021 05/08/2019 12/08/2021 05/08/2019 05/07/2021	04/27/2019 04/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020 05/27/2019 05/27/2020
Application Title 06/14/2019 06/14/2019 06/14/2019 06/14/2019 06/14/2019 06/14/2019 06/14/2019 06/14/2019 06/14/2019 06/14/2019 06/14/2019 06/14/2019	CB1671 C102 <	Priority Date Filing Date issue Date		Priority Date Filing Date Issue Date 05/08/2019 12/06/2021 05/08/2019 05/07/2020 05/08/2019 11/02/2021 05/08/2019 12/06/2021 05/08/2019 12/06/2021 05/08/2019 05/07/2020 05/08/2019 05/07/2020		Priority Darke Filing Darke issue Darke 05/08/2019 12/06/2021 05/08/2019 05/07/2020 05/08/2019 11/03/2021 05/08/2019 12/06/2021 05/08/2019 12/06/2021 05/08/2019 05/07/2022	

2seventy Ref. BLUE-140AU BLUE-140BR BLUE-140CA BLUE-140CA	22eventy Ref. 8U0E-13180 8U0E-13180 8U0E-13160 8U0E-13160 8U0E-13160 8U0E-13110 8U0E-13110 8U0E-13110 8U0E-13110 8U0E-13110 8U0E-13150 8U0E-13150 8U0E-13150 8U0E-13150	2veremty Ref. BUE-13080 BUE-13080 BUE-13060 BUE-13060 BUE-13060 BUE-13060 BUE-13080 BU	2seventy Ref. BLUE-129P1 BLUE-129PC BLUE-129USPC	2.000001 Ref BLIE-1258AU BLIE-1258AU BLIE-1258AU BLIE-1228BV BLIE-1228BV BLIE-1228BV BLIE-1228F BLIE-1228F BLIE-1228F BLIE-1228F BLIE-1228F BLIE-1228F	2seventy Ref Bulle-127AU BULE-127AU BULE-127CN BULE-127CN BULE-127P1 BULE-127P1 BULE-127P1 BULE-127P1 BULE-127P1	2seventy Ref. BLUE-125P1 BLUE-125US	BLUE-123/P BLUE-123/R BLUE-123/RX BLUE-123/RZ BLUE-123/RZ BLUE-123/RZ BLUE-123/RZ BLUE-123/RZ BLUE-123/RZ
RIGHTS Owned by Zseventy Owned by Zseventy Owned by Zseventy	RIGHTS Owned by Zeventry Owned by Zeventry	RIGHTS Owned by Zaventy Owned by Zaventy	RIGHTS Owned by 2seventy Owned by 2seventy Owned by 2seventy	RIGHTS Owned by Zeventry Owned by Zeventry	RIGHTS Owned by Zeventy Owned by Zeventy	RIGHTS Owned by 2seventy Owned by 2seventy	Owned by Zeeventy Owned by Zeeventy
CO AU 2022310862.0 BR BR1120240004724 CA 3225252.0	CO Sertal No. AU 2021.330958 BR BR11202200337.3 CA 3191855 CP 2021.8007491.5 EP 21862543.2 HK 6202.310461 IP 2036.21.240.2 IK 6202.312464 IP 2036.21.2002.27.3 MX MX/p2022.3/0022.73 MX MX/p2022.3/0022.73 NZ 7982.86 US 63/060744 US 63/060743 US 63/02021/0472.90 SG 112.02201136F US 18/0232.32	CO Serial No. AU 202124/591 AU 20212013980-7 CA 3177181 CA 3177181 CA 3177181 CA 2022976-4 EP 21775262.5 HK 62023073058.7 IL 206272-7036811 KR 10-2022/01266-2 MX MK/AD22012062-2 VI 6202201206-2 NZ 793783 US 62/000800 WO PCT/US2021/024370 SG 10202235384 SG 10202235384 US 61/2021448370	CO Serial No. US 63/007990 WO PCT/US2021/026597 US 17/917418	CO 25.128651 AU 202128651 CA 3194520 CN 202180631 FP 218210531 FP 218210531 FP 202257231 FP 202257231 FP 202257231 VS 65/032777 WO PCT/V5021/036840 SG 1120225048810 US 18/009239	CO 25-14140. AU 2021255702 CA 3180329 CI 202180028802.8 EP 21780053 HK 63023075915.6 JP 2022-2687711 KR 10-2022-7085279 US 63/011494 Wo PCT/US201/027648 US 17/918830	CO Serial No. US 62/925800 US 17/077134	p 2021-573844 KR 10-2022-7001320 MX MX/A/2021/015495 NZ 784726 US 62/861384 US 62/861384 WO PCT/US2020/037145 SG 11202136134 US 17/618747
Publication No.	Publication No. 3191855 116348496 4204457 2023-538591 10-2023-0053650 W02022046730 US-2023-0310604-A1	Publication No. 3177181 115482294 4126924 HK40083795 2023-519868 10-2022/012062 MK/A/2022/012062 WO 2021/195503 US-2023-0124640-A1	Publication No. WO 2021/207613 US-2023-0151117-A1	Publication No. 115698305 405199 4099154 10-2023-0214891 10-2023-021/252782 WO 2021/252782 US-2023-0212591-A3	Publication No. 3180329 115597864 40187131 40087431A 2003-522038 10-2023-0005147 WO 2021/211948	Publication No.	2022-537159 10-2022-0083485 784226 WO 2020/252110 US-2022-0280567-A3
Application The Enkineered T cell receptors fused to binding domains from Antibodies Enkineered T cell receptors fused to binding domains from Antibodies Enkineered T cell receptors fused to binding domains from Antibodies	BCMA CHMERIC ANTIGEN RECEPTORS BCMA CHMERIC ANTIGEN RECEPTORS	TCELL RECEPTORS TCELL RECEPTORS	FRB ANTIBODIES FRB ANTIBODIES FRB ANTIBODIES	METHODS FOR MANUFACTURING VIRAL VECTORS METHODS FOR MANUFACTURING VIRAL VECTORS	MODIFED CCR POLYPEPTIDES AND USES THEREO MODIFED CCR POLYPEPTIDES AND USES THEREO	CELL CULTURE MEDIUM CELL CULTURE MEDIUM	COMPOSITIONS AND METHODS FOR TREATING CANCER COMPOSITIONS AND METHODS FOR TREATING CANCER
DOMAI DOMAI DOMAI					ירי ודי ודי ודי ודי ודי ודי ודי ודי ודי		ANCER ANCER ANCER ANCER ANCER ANCER ANCER
Application Title DOMAINS FROM AVTIBODIES DOMAINS FROM AVTIBODIES DOMAINS FROM AVTIBODIES	Application Title	Application Title	Application Title	Application Title	n n n n n n n n n n n n n n n n n n n	Application Title	ANCER ANCER ANCER ANCER ANCER ANCER
Application Title Priority Date Filing Date Issue Date DOMAINS FROM ANTIBODES 07/14/2021 07/14/2022 07/14/2022 DOMAINS FROM ANTIBODES 07/14/2021 07/14/2022 07/14/2022 DOMAINS FROM ANTIBODES 07/14/2021 07/14/2022 07/14/2022	Application Title Printy Date (0.1/1/2023) Filing Date (0.1/1/2023) suse Date (0.1/1/2023) 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/2023 0.0/1/1/	Application Title Pind by the ela/217/2020 Filing Date ela/217/2020 Saw Date ela/217/2020	Application Title Priority Date Filing Date Issue Date 04/107/2020 04/10/2020 04/10/2020 04/10/2020 04/10/2020 04/06/2022 04/06/2022 04/06/2022			Application Title Priority Date Filing Date Issue Date 10/25/2019 10/25/2019 10/25/2019 10/25/2019 10/22/2020	AMEER 06/14/2019 06/11/2020 AMEER 06/14/2019 01/13/2022 AMEER 06/14/2019 01/13/2022 AMEER 06/14/2019 01/13/2022 AMEER 06/14/2019 01/13/2022 AMEER 06/14/2019 06/14/2019 AMEER 06/14/2019 06/14/2019 AMEER 06/14/2019 06/14/2019 AMEER 06/14/2019 06/11/2020 AMEER 06/14/2019 06/11/2020 AMEER 06/14/2019 06/13/2020 AMEER 06/14/2019 06/13/2020 AMEER 06/14/2019 06/13/2020 AMEER 06/14/2019 12/13/2021 AMEER 06/14/2019 12/13/2021
Priority Date Filing Date 07/14/2021 07/14/2022 07/14/2021 07/14/2022 07/14/2021 07/14/2022	Priority Date: Filing Date 08/25/0020 02/3/2023 08/25/0020 02/3/2023 08/25/0020 02/3/2023 08/25/0020 02/14/2023 08/25/0020 03/14/2023 08/25/2020 02/14/2023 08/25/2020 02/14/2023 08/25/2020 02/14/2023 08/25/2020 02/15/2023 08/25/2020 03/15/2023 08/25/2020 03/15/202	Priority Date: Gilling Date: 03/27/2020 00/25/2022 03/27/2020 00/25/2022 03/27/2020 00/25/2022 03/27/2020 00/25/2022 03/27/2020 00/25/2022 03/27/2020 00/25/2022 03/27/2020 00/25/2022 03/27/2020 00/25/2022 03/27/2020 03/27/2020 03/27/2020 03/27/2020 03/27/2020 03/25/2022 03/27/2020 03/25/2022 03/27/2020 03/25/2022	64/16/2020 04/16/2020 04/16/2020 04/16/2020 04/16/2020 04/16/2020 04/10/2020 10/16/2022	Application Title Priority Date Filing Date 06/11/2020 <	Application Title Priority Date Filing Date 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020 04/17/2020	Priority/Date Filing Date 10/25/2019 10/25/2019 10/25/2019 10/22/2020	06(14/2019 06(14/2019 06(14/2019 06(14/2019 06(14/2019 06(14/2019 06(14/2019 06(14/2019 06(14/2019 06(14/2019 06(14/2019 06(14/2019

2:eventy Ref. BULE-076.61 BULE-076.61 BULE-076.61 BULE-076.61 BULE-076.61 BULE-076.61 BULE-076.11 BULE-076.11 BULE-076.11 BULE-076.11 BULE-076.11 BULE-076.11 BULE-076.11 BULE-076.12 BULE-076.12 BULE-076.12 BULE-076.12 BULE-076.12 BULE-076.12 BULE-076.12 BULE-076.12 BULE-076.12 BULE-076.12 BULE-076.12 BULE-076.12 BULE-076.12	Zevenny Ker. BLUE-OHA, CH BLUE-OHA, CH BLU	Czewenty Ref. Zzewenty Ref. Zurodobi SULF-GAD ZH BLUE-GAD ZH BLUE-G	Zeeventy Ref. TSVT-004PC TSVT-004PC Zeeventy Ref. TSVT-005PC TSVT-005PC Zeeventy Ref. Zeeventy Ref.	2seventy Ref. TSVT-002P1 TSVT-002P1 TSVT-003PK 2seventy Ref. TSVT-003PC	BLUE-JAOCN BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR BLUE-JAOR
BIGHTS Owned by Zeventy Owned by Zeventy	BIGHTS Co-Ourned (cellectic/Jsavenny) Co-Ourned (cellectic/Jsavenny)	Co-Owned CalentifySCR Co-Owned CalentifySCR Co-Owned (CalentifySeventy) Co-Owned (CalentifySeventy)	RIGHTS Owned by Zeventy Owned by Zeventy Owned by Zeventy Owned by Zeventy Owned by Zeventy Owned by Zeventy Ch-Dund State	Co-Owned Assemity/AEGN Co-Owned Assemity/REGN Co-Owned 2-seventy/REGN Co-Owned by 2-seventy Owned by 2-seventy	Owned by Zerventy Owned Serventy/SCB
CO Seriel No. AU 2017232629 BB BR1120159046291 CS 17735,464 CS 3035455 EP 17849655.0 EP 237734.46 DF 023702024 ID F1020190224 ID F1020190224 ID F1020190227 ID F102019027 ID 2019-512872 ID 2019-512872 ID 2019-512872 ID 2019-512879 KR 10-5202-7094173 KR 10-5202-7004173 KR 10-5202-7004173 KR 10-5202-7004173 KR 10-5202-7004173 KR 10-5202-7004173 KR 10-5202-7004173 KR 10-5202-7004173 KR 10-5202-7004173 KR 10-5202-7004173 KR 10-5202-	Seriel Ma. AL 2012/27/80100 C4 2013/872.00 C4 147/2889.00 C5 147/2889.00 C6 147/2889.00 C7 147/2889.00 C6 147/2889.00 C7 147/2889.00 C6 147/2889.00 C7 147/2	63/493.467 63/502.875 021.273085.00 2012.273085.00 14727.480.00 14727.480.00 14727.480.00 14727.480.00 14727.480.00 14727.480.00 1511.488.00 1511.588.00 1511.588.00 1511.588.00 1511.588.00 1511.588.	CO Serial No. US 63/346001 Wo PCT/US2023/067406 CO Serial No. US 63/329003 No. US 63/329003 No. US 63/229003 No. US 63/229003 No. US 63/229003 Serial No. US 63/239065552 Serial No. US 63/404 AF7 No.	Serial No. 63/298141 PCT/US2023/010518 Serial No. 63/329003 PCT/US2023/065553	CN EP 22768562.5 IL 3095770 JP 2024-501757 KR E 2024-501757 US 63/221819 US 63/221819 US 63/221819 US 63/221819 US 63/221819 US 63/288468 US 63/288468
Publication No. (US-2022-0340626-A1 3035455 109923211 3510157 4248879 4248879 4248879 4248879 4248879 424005325 2019/07655 2019-5262668 10-2022-0140017 MX/a/2019/002725 2018049226	Publication No. 2012;72(39)1 2,913,872 3004338 3004338 3004338 3004338 3004338 3004338 3004338 3004338 3004338 3004338 11223273 3004338 11223273 3004338 11223273 3004338 1123373 3004338 112337373 112337373 1123373 1123373 11233737	Publication No. 2014.273089 2.913.8771 3004149 3004149 3004149 3004149 3004149 3004149 1223394 61482383 2014191525 10,006,052	Publication No. WO2023230512 Publication No. WO2023196996 Publication No.	Publication No. WO 2023/133358 Publication No. WO2023196997	WO 2023/288267 Publication No.
PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENCONUCLEASE VARIANTS. COMPOSITIONS, AND METHODS OF USE	A POLIDADO HOMING ENDONICIEASE CLEAVING THE TCRA GENE AND USES A MODIDAD HOMING ENDONICIEASE CLEAVING THE TCRA GENE AND USES A MODIDAD HOMING ENDONICIEASE CLEAVING THE TCRA GENE AND USES A MODIDAD HOMING ENDONICIEASE CLEAVING THE TCRA GENE AND USES A MODIDAD HOMING ENDONICIEASE CLEAVING THE TCRA GENE AND USES A MODIDAD HOMING ENDONICIEASE CLEAVING THE TCRA GENE AND USES A MODIDAD HOMING ENDONICIEASE CLEAV	CYTOKINE EXPRESSING FINAINEERED IMMINUE CELLS CYTOKINE EXPRESSING FINAINEERED IMMINUE CELLS Application Title A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMORINE RECEPTOR TYPE-5 (CCR5) (GENE AND USS A LADUDADG HOMING ENDONUCLEASE CLEAVING THE CC CHE	Application Title COMPOSITIONS AND USES THEREOF COMPOSITIONS AND USES THEREOF MULTIPARTITE RECEPTOR AND SIGNALING COMPLEXES MULTIPARTITE RECEPTOR AND SIGNALING	MUC16 CHIMERIC ANTIGEN RECEPTORS MUC16 CHIMERIC ANTIGEN RECEPTORS MULTIPARTITE RECEPTOR AND SIGNALING COMPLEXES MULTIPARTITE RECEPTOR AND SIGNALING COMPLEXES MULTIPARTITE RECEPTOR AND SIGNALING COMPLEXES	ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES ENGINEERED T CELL RECEPTORS FUSED TO RECEPTORS FUSED TO RECEPTOR FUSED TO R
Priority Date Filing Date Sisue Date 03/08/2016 65/08/2017 05/29/2023 03/08/2017 65/29/2023 03/08/2016 65/08/2017 03/08/2016 <td>Phonty Date Filing Date Sizue Date 05/41/2013 05/28/2014 05/62/2014 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/20</td> <td>Big Big Big<td>Priority Date Filing Date Issue Date 05/16/2002 05/26/2002 05/26/2002 05/26/2002 05/24/2002 05/24/2002 Priority Date Filing Date Issue Date 04/08/2002 04/08/2002 04/08/2002 04/08/2002 04/07/2002 04/07/2002 Priority Date Filing Date Issue Date Priority Date Filing Date Issue Date 04/08/2002 04/07/2003 Scuto 2004</td><td>Priority Date Elling Date Issue Date 01/10/2022 01/10/2023 01/10/2022 01/10/2023 Priority Date Filing Date Issue Date 04/08/2022 04/07/2023</td><td>-</td></td>	Phonty Date Filing Date Sizue Date 05/41/2013 05/28/2014 05/62/2014 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/2019 05/41/2013 05/28/2014 01/02/20	Big Big <td>Priority Date Filing Date Issue Date 05/16/2002 05/26/2002 05/26/2002 05/26/2002 05/24/2002 05/24/2002 Priority Date Filing Date Issue Date 04/08/2002 04/08/2002 04/08/2002 04/08/2002 04/07/2002 04/07/2002 Priority Date Filing Date Issue Date Priority Date Filing Date Issue Date 04/08/2002 04/07/2003 Scuto 2004</td> <td>Priority Date Elling Date Issue Date 01/10/2022 01/10/2023 01/10/2022 01/10/2023 Priority Date Filing Date Issue Date 04/08/2022 04/07/2023</td> <td>-</td>	Priority Date Filing Date Issue Date 05/16/2002 05/26/2002 05/26/2002 05/26/2002 05/24/2002 05/24/2002 Priority Date Filing Date Issue Date 04/08/2002 04/08/2002 04/08/2002 04/08/2002 04/07/2002 04/07/2002 Priority Date Filing Date Issue Date Priority Date Filing Date Issue Date 04/08/2002 04/07/2003 Scuto 2004	Priority Date Elling Date Issue Date 01/10/2022 01/10/2023 01/10/2022 01/10/2023 Priority Date Filing Date Issue Date 04/08/2022 04/07/2023	-
Stenus Stenus GRANTED PUBLISHED PUBLISHED GRANTED GRANTED GRANTED GRANTED GRANTED GRANTED GRANTED FUBLISHE	Stenus GRANTED GRANTED GRANTED GRANTED GRANTED GRANTED GRANTED GRANTED GRANTED GRANTED GRANTED	PENDING Status GRANTED PENDING GRANTED GRANTED GRANTED GRANTED GRANTED	Status PENDING PENDING Status PENDING Status	Status Expreed PENDING Status EXPIRED PENDING	TO BE FILED PENDING PENDING PENDING TO BE FILEG COV BE FILEG PUBLISHED PENDING PENDING Status EEVONG
Expiration Date 09/08/2037 09/08/2037 09/08/2037 09/08/2037 09/08/2037 09/08/2037	Explansion Date 65/28/2034 05/28/2034 05/28/2034 05/28/2034 05/28/2034 05/28/2034 05/28/2034 05/28/2034 05/28/2034 05/28/2034 05/28/2034 05/28/2034	05/17/2013 05/17/2013 05/28/2034 05/28/2034 05/28/2034 05/28/2034 05/28/2034 05/28/2034 05/28/2034	Expiration Date 05/26/2023 05/26/2023 Expiration Date 04/08/2023 05/01/2013	Expiration Date 01/10/2023 Expiration Date 04/08/2023	07/14/2022 Expiration Date 12/10/2022

2xeventy Ref. BLUE-109-AU BLUE-109-CN BLUE-109-CN BLUE-109-DN BLUE	BLUE-G87.NX BLUE-G87.NZ BLUE-G87.SG BLUE-G87.PC BLUE-G87.PC BLUE-G87.PC BLUE-G87.PC BLUE-G87.VSPC	BLUE-087.D1 BLUE-087.EP BLUE-087.IL BLUE-087.JP BLUE-087.JP BLUE-087.KR BLUE-087.KR	2seventy Ref. BLUE-087.C1 BLUE-087.C1 BLUE-087.C2 BLUE-087.CA BLUE-087.CA BLUE-087.CA	Zseventy Ref. BLUE-073:AU BLUE-073:CA BLUE-073:EP BLUE-073:EP BLUE-073:P1 BLUE-073:P1 BLUE-073:P2 BLUE-073:P2 BLUE-073:PC	2seventy Ref. BLILE-077 AU BLILE-077 CN BLILE-077 CN BLILE-077 EP BLILE-077 P2 BLILE-077 P2 BLILE-077 P2 BLILE-077 P2 BLILE-077 P2 BLILE-077 P2 BLILE-077 P2	BLUE-076.SG BLUE-076.USPC BLUE-076.ZA
RIGHTS Owned by Zeventy Owned by Zeventy	Owned by Zeventy Owned by Zeventy	Owned by Zseventy Owned by Zseventy	RIGHTS Owned by Zaeventy Owned by Zaeventy Owned by Zaeventy Owned by Zaeventy Owned by Zaeventy Owned by Zaeventy	RIGHTS Owned by Zeventy Owned by Zeventy Owned by Zeventy Owned by Zeventy Owned by Zeventy Owned by Zeventy Owned by Zeventy	RIGHTS Owned by Zaventry Owned by Zaventry	Owned by 2seventy Owned by 2seventy Owned by 2seventy
CO AU 2013959334 CA 3122091 CP 303905971 FP 198970571 HK 60022051747.3 IL 283274 IL 283274 IL 283274 JP 2021-532869 KR 10-2021-7020809 US 62/771/71 WO PCT/US2019/065223 US 62/771/871		US 17/150,223 EP 1806825.8 HK 62020015146.7 JP 2012-564837 JP 2012-166786 JP 2022-166786 KR 10-2013-7034661		CO Serial No. AU 201734688 CA 304012 EP 17861557.3 JP 2015-20527 JS 62/409,163 US 62/414,260 WO PCT/US2017/05/7014 US 16/341,228	CO 354761 No. AU 201742273 US 18/174,155 EP 1785944112 IF 2015-540312 JF 2015-540312 US 52/46,589 US 52/414,266 W/O PCT/US2017/056178 US 15/340,257	SG 11201901757Y US 16/330,039 ZA 2019/01384
Publication No. 3122094 31339013 3893866 40062239 20022-510481 10-2021-0102299 10-2021-0102299 US-2022-0177860-A1	2018218194 2020072059 US-2021-0147818	US 2021-0214714 A1 3630962 40025461 2020-521456 2020-521456 2020-2183262 10-2020-0011953 10-2023-0147767	Publication No. US-2020-0087653 US 2020-0109385 US 2021-0214700 3064014 CN110799644A	Publication No. 3040157 110050066 3526334 2019-535240 2018075541 US-2020-0123515	Publication No. US-2023-0357736-A1 110036107A 3534916 40012226 2019-532674 US-2022-0186198-A1 US-2022-0186198-A1	US-2021-0040165-A1
Application Title PCCD-1 HOMING ENCONUCLEASE VARIANTS PCCD-1 HOMING ENCONUCLEASE VARIANTS	Cale ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE Cale ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	CBLE ENCONLICLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE CBLE ENCONLICLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	Application Title CBLE ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE CBLE ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	Application Title TGFBeata2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE TGFBeata2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	Application Title TCPa. HOMING ENDONUCLEASE VARIANTS TCPa. HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE TCPa. HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE TCPa. HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE TCPa. HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE TCPa. HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE TCPa. HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE TCPa. HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE TCPA. HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
Priority Date 12/10/2018 12/10/2018 12/10/2018 12/10/2018 12/10/2018 12/10/2018 12/10/2018 12/10/2018 12/10/2018 12/10/2018 12/10/2018		05/25/2017 05/25/2017 05/25/2017 05/25/2017 05/25/2017 05/25/2017 05/25/2017 05/25/2017		Priority Date 10/17/2016	Priority Date 1 10/11/2016 1	09/08/2016 0 09/08/2016 0 09/08/2016 0
Filing Date Issu 12/09/2019 12/09/2019 12/09/2019 12/09/2019 12/09/2019 12/09/2019 12/09/2019 12/09/2019 12/09/2019 12/09/2019 12/09/2019 12/09/2019 12/09/2019		01/15/2021 08/2 05/25/2018 05/25/2018 05/25/2018 12/0 05/25/2018 12/0 10/18/2022 10/12/2023 10/1		Filing Date Issu 10/17/2017 10/17/2017 10/17/2017 10/17/2017 10/17/2017 10/17/2016 10/17/2016 10/17/2016 10/17/2017 10/17/2017 10/17/2017 10/17/2017	Filing Date Issu 10/11/2017 10/11 02/24/2023 10/11/2017 10/11/2017 10/11/2017 06/02/2020 06/1 10/11/2017 06/1 10/11/2017 10/11/2016 10/11/2016 10/11/2016 10/11/2017 06/2 10/11/2017 06/1 10/11/2017 06/2 10/11/2017 06/2 10/11/2017 06/2 10/11/2017 06/2 10/11/2017 06/2 10/11/2017 06/2 10/11/2017 06/2 10/11/2017 06/2 10/11/2017 06/2 10/11/2017 06/2 10/11/2017 06/2 10/2/2020 02/2	09/08/2017 03/01/2019 06/2 09/08/2017
יינער אינער אי אינער אינער אינ	08/31/2022	08/22/2023 PI 12/08/2022 10/12/2023 PI 10/12/2023 PI		Issue Date P P 04/18/2022 12/20/2022	Io/19/2023 PP PP PP PP PP PP PP PP PP PP PP PP PP	06/21/2022 G P
Status PENDING PUBLISHED PUBLISHED PUBLISHED PUBLISHED PUBLISHED PUBLISHED PUBLISHED PUBLISHED PUBLISHED PUBLISHED	PENDING GRANTED PENDING PENDING INACTIVE INACTIVE INACTIVE INACTIVE	GRANTED PUBLISHED PUBLISHED PENDING GRANTED GRANTED GRANTED GRANTED	Status PENDING GRANTED GRANTED GRANTED PUBLISHED PUBLISHED PUBLISHED	Status PENDING PUBLISHED PUBLISHED PUBLISHED GRANTED INACTIVE INACTIVE GRANTED	Status GRAVTED PUBLISHED PUBLISHED PUBLISHED PUBLISHED IGRANTED INACTIVE INACTIVE GRANTED GRANTED	PENDING GRANTED PENDING
Expiration Date	05/25/2038	09/16/2038 05/25/2038 05/25/2038	Expiration Date 05/25/2038 10/04/2038	Expiration Date 10/17/2037 01/08/2040	Expiration Date 10/11/2037 10/11/2037 06/30/2040	09/22/2038